SEC Form 4 · accession 0000891293-18-000085
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred Telling
Director
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $1.88 | Sep 18, 2018 | A | 60,000 | A | — | Sep 18, 2028 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The option grant shall be fully vested and exercisable effective on the later of the Resignation Date or the effective date of the release as long as Dr. Telling remains in good standing on the Board with the Company through the Resignation Date.